1887
Rapid communication Open Access
Like 0

Abstract

During the 2024/25 influenza season, enhanced and standard-dose influenza vaccines were available for individuals aged 65 and older. Compared with the standard-dose quadrivalent influenza vaccine (QIV), the adjuvanted QIV was significantly more effective, with an overall vaccine effectiveness (VE) of 48% (95% CI: 42–52) vs 33% (95% CI: 24–41) when considering both non-hospitalised and hospitalised patients. The high-dose QIV demonstrated similar effectiveness to the adjuvanted QIV. These findings support the inclusion of enhanced influenza vaccines in future vaccination programmes.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.12.2500174
2025-03-27
2025-04-01
/content/10.2807/1560-7917.ES.2025.30.12.2500174
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/12/eurosurv-30-12-2.html?itemId=/content/10.2807/1560-7917.ES.2025.30.12.2500174&mimeType=html&fmt=ahah

References

  1. Schønning K, Dessau RB, Jensen TG, Thorsen NM, Wiuff C, Nielsen L, et al. Electronic reporting of diagnostic laboratory test results from all healthcare sectors is a cornerstone of national preparedness and control of COVID-19 in Denmark. APMIS. 2021;129(7):438-51.  https://doi.org/10.1111/apm.13140  PMID: 33949007 
  2. Grove Krause T, Jakobsen S, Haarh M, Mølbak K. The Danish vaccination register. Euro Surveill. 2012;17(17):2.  https://doi.org/10.2807/ese.17.17.20155-en  PMID: 22551494 
  3. Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J Public Health. 2011;39(7) Suppl;30-3.  https://doi.org/10.1177/1403494811401482  PMID: 21775347 
  4. Emborg HD, Vestergaard LS, Botnen AB, Nielsen J, Krause TG, Trebbien R. A late sharp increase in influenza detections and low interim vaccine effectiveness against the circulating A(H3N2) strain, Denmark, 2021/22 influenza season up to 25 March 2022. Euro Surveill. 2022;27(15):2200278.  https://doi.org/10.2807/1560-7917.ES.2022.27.15.2200278  PMID: 35426361 
  5. Kissling E, Maurel M, Emborg HD, Whitaker H, McMenamin J, Howard J, et al. Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023. Euro Surveill. 2023;28(21):2300116.  https://doi.org/10.2807/1560-7917.ES.2023.28.21.2300116  PMID: 37227299 
  6. Rose AM, Lucaccioni H, Marsh K, Kirsebom F, Whitaker H, Emborg HD, et al. Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025. Euro Surveill. 2025;30(7):2500102.  https://doi.org/10.2807/1560-7917.ES.2025.30.7.2500102  PMID: 39980423 
  7. Separovic L, Zhan Y, Kaweski SE, Sabaiduc S, Carazo S, Olsha R, et al. Interim estimates of vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) during a delayed influenza season, Canada, 2024/25. Euro Surveill. 2025;30(4):2500059.  https://doi.org/10.2807/1560-7917.ES.2025.30.4.2500059  PMID: 39885824 
/content/10.2807/1560-7917.ES.2025.30.12.2500174
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error